Propanc Biopharma公司宣布,将启动两项独立的II期临床研究,分别针对胰腺癌和卵巢癌患者。据悉,每项研究计划招募60名参与者,以评估其候选疗法的安全性与有效性。这一举措标志着该公司在推进其肿瘤治疗管线方面迈出了重要一步。
Propanc Biopharma公司宣布,将启动两项独立的II期临床研究,分别针对胰腺癌和卵巢癌患者。据悉,每项研究计划招募60名参与者,以评估其候选疗法的安全性与有效性。这一举措标志着该公司在推进其肿瘤治疗管线方面迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.